Related Experiment Video
Updated: Jul 15, 2026

Assessment of Social Transmission of Food Preferences Behaviors
Published on: January 25, 2018
Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy
1Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Background:
Late-onset type I familial amyloid polyneuropathy (FAP TTR Met30) cases unrelated to endemic foci in Japan show clinical features setting them apart from early-onset cases in endemic foci.
Objective:
To compare pathologic features between the early- and late-onset types.
Methods:
Pathologic findings in FAP TTR Met30 with onset before age 50 in relation to endemic foci (11 cases) were compared with those in 11 later-onset cases unrelated to endemic foci.
Results:
Sural nerve biopsy specimens showed predominantly small-fiber loss in early-onset cases; variable fiber size distribution, axonal sprouting, and relatively preserved unmyelinated fibers characterized late-onset cases. Autopsy cases representing both groups showed amyloid deposition throughout the length of nerves and in sympathetic and sensory ganglia, but amounts were greater in early-onset cases. Amyloid deposition and neuronal cell loss were greater in sympathetic than dorsal root ganglia in early-onset cases; the opposite was true in late-onset cases. Size assessment of remaining neurons in these ganglia suggested predominant loss of small neurons in early-onset cases but loss of neurons of all sizes in late-onset cases. Transthyretin-positive, Congo red-negative amorphous material was more conspicuous in nerves from late- than early-onset cases. In extraneural sites, amyloid was more conspicuous in thyroid and kidney from early-onset cases and in heart and hypophysis from late-onset cases. In early-onset cases, cardiac amyloid deposition was prominent in the atrium and subendocardium but was conspicuous throughout the myocardium in late-onset cases.
Conclusion:
The pathology of early- and late-onset FAP TTR Met30 correlated well with differences in clinical findings.
Insights
Pathologic differences in familial amyloid polyneuropathy (FAP TTR Met30) correlate with age of onset. Early-onset FAP TTR Met30 shows small-fiber loss, while late-onset FAP TTR Met30 exhibits distinct nerve and ganglion pathology.
Area of Science:
- Neuropathology
- Amyloidosis Research
- Genetics of Neurological Disorders
Background:
- Familial amyloid polyneuropathy (FAP TTR Met30) presents with distinct clinical features based on age of onset and geographic origin.
- Late-onset FAP TTR Met30 cases, unrelated to Japanese endemic foci, differ clinically from early-onset cases in endemic areas.
Purpose of the Study:
- To conduct a comparative pathological analysis of early- and late-onset FAP TTR Met30.
- To elucidate the distinct neuropathological characteristics associated with different FAP TTR Met30 phenotypes.
Main Methods:
- Comparative pathological examination of sural nerve biopsies and autopsy tissues from 11 early-onset and 11 late-onset FAP TTR Met30 patients.
- Assessment of amyloid deposition, neuronal cell loss, and fiber characteristics in peripheral nerves and autonomic/sensory ganglia.
Main Results:
- Early-onset FAP TTR Met30 showed predominantly small-fiber loss, while late-onset cases displayed variable fiber sizes and axonal sprouting.
- Amyloid deposition was more extensive in early-onset cases, with differential distribution in sympathetic versus sensory ganglia.
- Late-onset cases showed more transthyretin-positive, Congo red-negative material and distinct extraneural amyloid deposition patterns (e.g., heart, hypophysis).
Conclusions:
- Pathological findings in FAP TTR Met30 align with observed clinical variations between early- and late-onset presentations.
- Distinct neuropathological profiles contribute to the differing clinical manifestations of FAP TTR Met30 based on onset age.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Diabetic Neuropathy
Alzheimer Disease l: Introduction
Alzheimer Disease ll: Pathophysiology
Parkinson Disease ll: Pathophysiology
Huntington Disease l: Introduction

